GMCSF treatment associated with improved cognition in cancer patients
Growth factors shown to cure Alzheimer's disease in a mouse model and administered to cancer patients as part of their treatment regimen were linked to significant improvements in the patients' cognitive function following stem cell transplantation, a preliminary clinical study reports.
The findings by researchers at the USF Health Byrd Alzheimer's Institute and Moffitt Cancer Center are reported online in Brain Disorders & Therapy.
The retrospective study showed that cancer patients treated with granulocyte macrophage colony stimulating factor (GMCSF) plus granulocyte colony stimulating factor (GCSF) experienced greater improvement in memory and thinking than those treated with GCSF alone.
In the new study, the USF and Moffitt researchers investigated the link between GMCSF and cognitive functioning in humans for the first time, said principal investigator Huntington Potter, PhD, professor of molecular medicine at the USF Health Byrd Alzheimer's Institute. While the research looked at changes in cognition related to cancer treatment, it provided the basis for a new randomized controlled trial at the Byrd Alzheimer's Institute testing the safety and effectiveness of GMCSF (the drug sargramostim) in 40 patients with mild to moderate Alzheimer's disease.
GMCSF and GCSF, routinely administered to patients undergoing transplants to treat blood or bone marrow cancers, have a proven safety track record for this use. These growth, or colony stimulating, factors boost blood-forming stem cells circulating in the patient's own blood before the cells are harvested for autologous hematopoietic cell transplantation (HCT), speed the repopulation of cells depleted by chemotherapy or radiation, and/or fight infection in patients receiving bone marrow or blood stem cells from a donor.
Those involved in cancer research and clinical care are aware that problems with memory and concentration, referred to as "chemo brain," can be a side effect of high-dose chemotherapy, which is part of the regimen accompanying HCT.
Previous University of South Florida (USF) studies by Dr. Potter, Tim Boyd, PhD, and others investigated GMCSF and GCSF separately in mice bred to develop symptoms of Alzheimer's disease. They showed that these growth factors both reduce beta amyloid, a substance forming the hallmark plaques in the brain associated with Alzheimer's, and reverse memory impairment, with GMCSF being more effective.
"This preliminary work is an intriguing first step and points to the importance of collaboration between different health disciplines," said lead author Heather Jim, PhD, assistant professor in the Health Outcomes and Behavior Department at Moffitt. "While more research is needed, the study suggests that GMCSF, a drug with a relatively good safety profile, may be able to either prevent or reverse cognitive decline not only in Alzheimer's patients, but cancer patients as well."
The USF-Moffitt study involved 19 cancer patients who received GMCSF and GCSF, and 76 who received GCSF only. No patients received GMCSF only. Most were diagnosed with multiple myeloma or non-Hodgkin's lymphoma and treated with autologous HCT.
Neuropsychological tests of memory, attention and executive function (complex thinking) conducted before patients received GMCSF and/or GCSF for treatment with HCT indicated significant cognitive impairment in all study participants. The same tests six months after HCT showed that group of patients administered GMCSF and GCSF performed significantly better than the group receiving GCSF only in the area of memory improvement. By 12 months, there were no differences; both groups had improved significantly in memory and executive function.
"The GMCSF was associated with faster cognitive recovery," Potter said.
The finding that GMCSF plus GCSF was associated with initially greater cognitive improvement than GCSF alone may reflect GMCSF's ability to mobilize a broader range of cell types, particularly the recruitment of more immune cells known as microglia that rush to damaged or inflamed areas to get rid of toxic substances, Potter said.
"Although preliminary and retrospective," he added, "the current data indicate that colony stimulating factors, particularly GMCSF, should be further tested as cognition enhancers for a number of different indications, including cancer and neurodegenerative disease."
Journal reference: Brain Disorders & Therapy
Provided by University of South Florida
- Blood stem cell growth factor reverses memory decline in mice Jul 01, 2009 | not rated yet | 0
- Mystery ingredient in coffee boosts protection against Alzheimer's disease Jun 21, 2011 | not rated yet | 0
- Rheumatoid arthritis signaling protein reverses Alzheimer's disease in mouse model Aug 23, 2010 | not rated yet | 0
- Tobacco-derived compound prevents memory loss in Alzheimer's disease mice Apr 27, 2011 | not rated yet | 0
- Treating high blood pressure, cholesterol, diabetes may lower risk of Alzheimer's disease Apr 13, 2011 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
1 hour ago Alright, so in Pathfinder (like Dungeons and Dragons) there's a spell that allows you to lift/move stuff within 25 ft with 5 pounds of force. A...
3 hours ago So energy can only be converted... So when you squeeze the bulb on a blood pressure cuff, you are applying kinetic energy. Then the cuff fills with...
How does momentum, inertia and drag affect the motion of an object?
6 hours ago How does momentum and inertia affect changes in speed, when considering acceleration from thrust, or from decelleration from drag? Say, for a...
What is Time-Varying Voltage?
7 hours ago In circuits, we have no problem saying that the voltage difference between two point is [itex]\cos(\omega t)[/itex], but what does that actually...
Contextual Relationships Between Momentum, Energy, and Force.
9 hours ago *I apologize in advance for the length of this post, if you wish to reduce reading skip to paragraph 5. Or if you are super lazy, the final...
Barometric pressure and the math behind it. Very interesting, I think.
10 hours ago Hey guys, I was actually researching the life of Edmond Halley and discovered that he discovered the relationship between barometric pressure and the...
- More from Physics Forums - Classical Physics
More news stories
(Medical Xpress)—Working with lab mice models of multiple sclerosis (MS), UC Davis scientists have detected a novel molecular target for the design of drugs that could be safer and more effective than current FDA-approved ...
Alzheimer's disease & dementia 12 hours ago | 5 / 5 (2) | 0 |
(HealthDay)—Older individuals with nonmelanoma skin cancer (NMSC) seem to have a significantly reduced risk of developing Alzheimer's disease (AD), according to a study published online May 15 in Neurology.
Alzheimer's disease & dementia May 16, 2013 | 5 / 5 (1) | 0
People who have skin cancer may be less likely to develop Alzheimer's disease, according to new research published in the May 15, 2013, online issue of Neurology®, the medical journal of the American Academy of Neurology. The li ...
Alzheimer's disease & dementia May 15, 2013 | 5 / 5 (1) | 0 |
(Medical Xpress)—Scientists at Washington University School of Medicine in St. Louis have helped identify many of the biomarkers for Alzheimer's disease that could potentially predict which patients will develop the disorder ...
Alzheimer's disease & dementia May 14, 2013 | 3 / 5 (1) | 0 |
A drug developed by scientists at the Salk Institute for Biological Studies, known as J147, reverses memory deficits and slows Alzheimer's disease in aged mice following short-term treatment. The findings, ...
Alzheimer's disease & dementia May 13, 2013 | 4.2 / 5 (5) | 0 |
Big names in medicine are set to give an upbeat assessment of the war on AIDS on Tuesday, 30 years after French researchers identified the virus that causes the disease.
2 hours ago | not rated yet | 0
For combat veterans suffering from post-traumatic stress disorder, 'fear circuitry' in the brain never rests
Chronic trauma can inflict lasting damage to brain regions associated with fear and anxiety. Previous imaging studies of people with post-traumatic stress disorder, or PTSD, have shown that these brain regions can over-or ...
3 hours ago | not rated yet | 0 |
The neural machinery underlying our olfactory sense continues to be an enigma for neuroscience. A recent review in Neuron seeks to expand traditional ideas about how neurons in the olfactory bulb might encode information about ...
14 hours ago | not rated yet | 0 |
(Medical Xpress)—What if the quality of your work depends more on your focus on the piano keys or canvas or laptop than your musical or painting or computing skills? If target users can be convinced, they ...
15 hours ago | 3.7 / 5 (3) | 0 |
In 2008 researchers from the University of Southern Denmark showed that the drug thioridazine, which has previously been used to treat schizophrenia, is also a powerful weapon against antibiotic-resistant bacteria such as ...
12 hours ago | 3.7 / 5 (3) | 0 |
In order to avoid harms associated with alcohol consumption, in 2009 the National Institute on Alcohol Abuse and Alcoholism issued guidelines that define low-risk drinking. These guidelines differ for men and women: no more ...
12 hours ago | not rated yet | 0 |